Romidepsin treatment for relapsed or refractory peripheral and cutaneous T‐cell lymphoma: Real‐life data from a national multicenter observational study
S Shimony, N Horowitz, E Ribakovsky… - Hematological …, 2019 - Wiley Online Library
Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T‐cell …
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T‐cell …
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study
S Shimony, N Horowitz, E Ribakovsky… - Hematological …, 2019 - pubmed.ncbi.nlm.nih.gov
Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T-cell …
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T-cell …
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
S Shimony, N Horowitz, E Ribakovsky… - Hematological …, 2019 - europepmc.org
Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T-cell …
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T-cell …